Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Pfenex Inc (PFNX)

Pfenex Inc (PFNX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 437,287
  • Shares Outstanding, K 34,297
  • Annual Sales, $ 50,330 K
  • Annual Income, $ 1,060 K
  • 60-Month Beta 1.32
  • Price/Sales 8.70
  • Price/Cash Flow 140.98
  • Price/Book 5.90
Trade PFNX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.23
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/05/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.21
  • Number of Estimates 3
  • High Estimate -0.18
  • Low Estimate -0.22
  • Prior Year 0.09
  • Growth Rate Est. (year over year) -333.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.51 +1.92%
on 08/31/20
12.95 -1.54%
on 09/03/20
+0.20 (+1.59%)
since 08/28/20
3-Month
6.91 +84.52%
on 07/31/20
13.38 -4.71%
on 08/11/20
+4.40 (+52.69%)
since 06/30/20
52-Week
5.26 +142.40%
on 05/01/20
14.00 -8.93%
on 02/18/20
+4.31 (+51.07%)
since 09/30/19

Most Recent Stories

More News
Ligand Completes Acquisition of Pfenex Inc.

--Acquired company expected to increase Ligand's royalties by 50% annually and to contribute $60 million of total revenue in 2023

PFNX : 12.75 (-0.08%)
LGND : 83.07 (-1.60%)
Ligand Announces Expiration of Tender Offer for Shares of Pfenex Inc.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Pfenex Inc. (NYSE American: PFNX) at an...

PFNX : 12.75 (-0.08%)
LGND : 83.07 (-1.60%)
Lifshitz Law Firm, P.C. Announces Investigation of Pfenex Inc. (NYSE: PFNX), Proteostasis Therapeutics, Inc. (NASDAQ: PTI), Rosetta Stone Inc. (NYSE:RST) and Yintech Investment Holdings Limited (NASDAQ: YIN)

EQNX::TICKER_START (NYSE MKT:PFNX),(NASDAQ:PTI),(NYSE:RST),(NASDAQ:YIN), EQNX::TICKER_END

PFNX : 12.75 (-0.08%)
PTI : 1.0100 (-0.98%)
YIN : 7.28 (+1.11%)
RST : 29.99 (unch)
INVESTIGATION ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm - MXIM, JCAP, GLIBA, PFNX

Halper Sadeh LLP, a global investor rights law firm, is investigating:

ADI : 118.48 (+1.73%)
MXIM : 70.19 (+2.06%)
JCAP : 17.27 (+0.06%)
GLIBA : 78.22 (+0.29%)
PFNX : 12.75 (-0.08%)
Lifshitz Law Firm, P.C. Announces Investigation of Cellular Biomedicine Group, Inc. (NASDAQ: CBMG), GCI Liberty, Inc. (NASDAQ: GLIBA), Maxim Integrated Products (NASDAQ:MXIM), National General Holdings Corp. (NASDAQ: NGHC), Pfenex Inc. (NYSE: PFNX), Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), and Varian Medical Systems, Inc. (NYSE: VAR)

, /PRNewswire/ --

MDSY : 0.73 (+4.29%)
CBMG : 18.28 (+0.33%)
GLIBA : 78.22 (+0.29%)
JCAP : 17.27 (+0.06%)
ADI : 118.48 (+1.73%)
NGHC : 33.99 (+0.12%)
OTEL : 11.51 (+0.17%)
PFNX : 12.75 (-0.08%)
SBPH : 1.1046 (+2.28%)
VAR : 172.28 (-0.08%)
MXIM : 70.19 (+2.06%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm - MJCO, PFNX, MXIM, GRUB

, /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating:

MJCO : 16.00 (+0.19%)
PFNX : 12.75 (-0.08%)
MXIM : 70.19 (+2.06%)
GRUB : 74.76 (-0.97%)
Moore Kuehn Encourages SBPH, PFNX, VAR, and PRNB Investors to Contact Law Firm

Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders....

SBPH : 1.1046 (+2.28%)
PFNX : 12.75 (-0.08%)
VAR : 172.28 (-0.08%)
PRNB : 100.05 (+0.10%)
Lifshitz Law Firm, P.C. Announces Investigation of Otelco Inc. (NASDAQ: OTEL), Pfenex Inc. (NYSE: PFNX), Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), and Varian Medical Systems, Inc. (NYSE: VAR)

EQNX::TICKER_START (NASDAQ:OTEL),(NYSE MKT:PFNX),(NASDAQ:SBPH),(NYSE:VAR), EQNX::TICKER_END

MDSY : 0.73 (+4.29%)
OTEL : 11.51 (+0.17%)
PFNX : 12.75 (-0.08%)
SBPH : 1.1046 (+2.28%)
VAR : 172.28 (-0.08%)
WeissLaw LLP Reminds PFNX and PRNB Shareholders About Its Ongoing Investigations

, /PRNewswire/ --

PFNX : 12.75 (-0.08%)
PRNB : 100.05 (+0.10%)
Ligand Commences Previously Announced Cash Tender Offer to Acquire Pfenex Inc.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its wholly-owned subsidiary, Pelican Acquisition Sub, Inc. (the "Purchaser"), is commencing a tender offer to purchase all outstanding...

PFNX : 12.75 (-0.08%)
LGND : 83.07 (-1.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Pfenex Inc. is a clinical-stage biotechnology company developing and commercializing proteins. The company's lead product candidate is PF582, a biosimilar candidate to Lucentis, for the potential treatment of patients with retinal diseases. It leverages its Pf'nex Expression Technology (TM) platform...

See More

Key Turning Points

2nd Resistance Point 13.01
1st Resistance Point 12.88
Last Price 12.75
1st Support Level 12.68
2nd Support Level 12.61

See More

52-Week High 14.00
Last Price 12.75
Fibonacci 61.8% 10.66
Fibonacci 50% 9.63
Fibonacci 38.2% 8.60
52-Week Low 5.26

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar